Stealth BioTherapeutics Announces The Appointment Of Mark P. Colonnese As Chief Financial Officer

Stealth BioTherapeutics (formerly Stealth Peptides), a clinical-stage biopharmaceutical company developing investigational drugs for the treatment of diseases involving mitochondrial dysfunction, today announced the appointment of Mark P. Colonnese as Chief Financial Officer. Mr. Colonnese brings nearly 30 years of experience in senior management roles leading business growth and financial strategies for life sciences companies.

Help employers find you! Check out all the jobs and post your resume.